INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		09787840			
Filing Date		2001-07-06			
First Named Inventor Mark		Leslie Smythe			
Art Unit		1656			
Examiner Name Chih I		Min Kam			
Attorney Docket Number		36677 8 (4050 001100)			

				Attorn	ley Duc	ket Number	30077.0 (4030.0	201100)		
					U.S.	PATENTS			Remove	_
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C	Date	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Lines v rant Passages or l es Appear	
	1									
If you wisi	h to a	l dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add	_
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation			s,Columns,Lines v rant Passages or l es Appear		
	1									
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ad	dd butto		
				FOREIG	GN PAT	TENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cite Document		Pages, Columns, where Relevant Passages or Rele Figures Appear	Τs
	1									
	2									
If you wisl	h to a	dd additional Foreign Pi	atent Do	cument	citation	information pl	lease click the Ad	d buttor	Add	_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	_

Examine Initials*	r Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Abstract, Molecular Modeling of Proteins & Nucleoc Acids, Dept of Biochemistry, Virginia Tech, QSAR and Drug Design, Retrieved from /www.biochem.vt.edu/modeling/qsar_drug html on June 28, 2006 pp. 1-12	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTIO Patient Documents at year USPTIO_CODE or MREP 901.6.2 Eachs office that issued the document, by the how-lefter code (WIPO Standard ST3,) 3 For Juspanese patient Counterest, by indication of the year of the response many personable research number of the period return personable research number of the period return personable research number of the period recomment, 4 fixed of document by the appropriate symbols as indicated on the document under WIPO Standard ST,16 if possible. § Applicant is to place a check mark here if English Bingquise the installation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		09787840		
	Filing Date		2001-07-06		
	First Named Inventor Mark		Leslie Smythe	_	
	Art Unit		1656		
Examiner Name Chih I		Chih	Min Kam		
	Attorney Docket Number		36677.8 (4050.001100)	Τ	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(v)C).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Mark D. Moore Ph.D.

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

42 gn3

Total of the signature.							
Signature	/Mark D. Moore/	Date (YYYY-MM-DD)	2006-10-25				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Comments o

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95-79) requires that you be given centain information in connection with your submission of the stacked form related to a penter application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is SU S. C. (2b)(2); (2) furnishing of the information solicided to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patent and Trademan XOTIEs is to process and/or examine your submission related to a patent agricultant or patent. If you do not furnish the requested process and/or examine your submission related to a patent agricultant or patent. If you do not furnish the requested requirement of the patent of the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the suited matter of the record
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals or part individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S. C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the accord was filed in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application peen to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.